ASTRAZENECA overnight
announced an agreement for
the acquisition of a 55% stake
in Netherlands-founded biotech
Acerta Pharma.
The US$4 billion deal includes
an upfront payment $2.5 billion
and a further $1.5 billion when
the company’s cancer drug
acalabrutinib is approved in the US.
There is also an option for AZ
to purchase the remaining 45%
of Acerta for US$3 billion, with
AstraZeneca ceo Pascal Soriot
saying the deal is “consistent with
our focus on long term growth and
reflects the role targeted business
development plays in our business
model”.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jan 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.